uniQure NV (NASDAQ:QURE) shares shot up 8.4% on Tuesday . The company traded as high as $8.06 and last traded at $7.99, with a volume of 406,515 shares changing hands. The stock had previously closed at $7.37.

A number of brokerages recently weighed in on QURE. Piper Jaffray Cos. restated a “buy” rating on shares of uniQure NV in a research report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of uniQure NV in a research report on Thursday, July 28th. WallachBeth Capital lowered their price objective on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, June 15th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $23.00 price objective on shares of uniQure NV in a research report on Wednesday, June 15th. Finally, Chardan Capital set a $35.00 price objective on shares of uniQure NV and gave the company a “buy” rating in a research report on Thursday, July 28th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. uniQure NV presently has a consensus rating of “Buy” and an average price target of $30.00.

The stock’s market capitalization is $198.55 million. The stock has a 50 day moving average price of $7.72 and a 200 day moving average price of $12.24.

uniQure NV (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. Equities analysts anticipate that uniQure NV will post ($3.51) EPS for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.